Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Lung Cancer

Novocure and Zai Lab Announces Pivotal LUNAR Study in NSCLC

Posted on January 9, 2023
Post Views: 254

Lung CancerZai Lab Limited and Novocure have announced the LUNAR study met its primary endpoint. It demonstrates statistically significant and clinically meaningful improvement in overall survival. LUNAR is a pivotal study to test the safety and effectiveness of Tumor Treating Fields (TTFields) along with standard therapies for stage 4 non-small cell lung cancer. This study has showed a statistically significant and clinically meaningful improvement among patients treated with TTFields and Immune Checkpoint Inhibitors in comparison with those treated with ICI alone. It showed positive overall survival when patients were treated with both TTFields and docetaxel as compared to docetaxel alone.

William Doyle, Novocure’s Executive Chairman said, We are pleased with the positive readout of the LUNAR study. Prior to LUNAR, the last phase 3 trial to lead to significant improvement in overall survival in late-stage, platinum-resistant non-small cell lung cancer was six years ago, underlining the difficulty in treating this disease.” “We are also pleased by the profound performance of the TTFields together with immunotherapy, which has the potential to meaningfully extend patient survival beyond what was previously possible,” he added.

NSCLC accounts for about 85% of all lung cancer and about 193000 patients are diagnosed with NSCLC each year in the U.S. It has been observed that approximately 46000 patients receive second-line treatment for stage 4 non-small cell lung cancer each year in the U.S. The primary endpoint is superior overall survival of patients with TTFields and immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone.

Novocure plans to release the full results of the LUNAR study in the future medical conference. It expects to file a Premarket Approval application with U.S. FDA in 2023.

The information shared in this blog is for educational purposes only. You should always consult your healthcare professional for any medical needs.

Subscribe to our newsletter or follow us on Twitter or Facebook today and never miss an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,324)
  • Lung Cancer: Symptoms and Treatment (5,655)
  • What is Non-Small-Cell Lung Cancer? (5,551)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d